相关实验视频
Updated: Jun 3, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.5K
营养药和补充剂在糖尿病前期和糖尿病管理中的作用
Giuseppe Derosa1,2,3, Angela D'Angelo1, Fabrizio Angelini4
1SINut-Società Italiana di Nutraceutica, Via Guelfa, 9, 40138 Bologna, Italy.
Nutrients
|January 11, 2025
概括
营养保健品和补充剂可能有助于控制糖尿病的前身 - - 失糖症. 本综述为医疗保健专业人员提供了关于使用这些选择来可能延迟糖尿病进展的见解.
科学领域:
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
- 营养科学 营养科学
背景情况:
- 失糖症,包括禁食葡萄糖 (IFG) 和葡萄糖耐受性 (IGT) 的受损,先于2型糖尿病.
- 生活方式干预 (饮食,运动) 是失糖症的主要管理策略.
- 营养药在治疗失糖症中的作用需要进行系统的评估.
研究的目的:
- 对营养保健品在治疗糖尿病和糖尿病前期的疗效进行系统审查.
- 为医疗保健专业人员提供关于营养药物干预的全面资源.
- 探索推迟或预防从失糖症到糖尿病的进展的策略.
主要方法:
- 系统的文献审查.
- 分析研究调查营养药对葡萄糖代谢障碍的研究.
- 来自领先的糖尿病和营养学会的专家共识.
主要成果:
- 有证据表明,某些营养药可能在管理IFG和IGT方面有好处.
- 营养药,作为生活方式变化的辅助剂,显示出延迟糖尿病发病的潜力.
- 该综述综合了来自不同科学视角的发现.
结论:
- 营养药物对患有失糖症的人来说是一个潜在的治疗途径.
- 需要进一步研究以确定最佳使用和具体建议.
- 这篇评论是临床医生管理糖尿病前期和糖尿病的宝贵指南.
相关概念视频
Diabetes: Management and Pharmacotherapy
233
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
233
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
152
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
152
Oral Hypoglycemic Agents: Biguanides and Glitazones
165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Hypoglycemia and Glucagon
150
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
150

